Brean Murray Carret & Co. Starts Ventrus Biosciences (VTUS) at Buy; Strong Clinical Data Weeks Away
Tweet Send to a FriendGet Alerts VTUS Hot Sheet
Price: $2.21 +0.91%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade VTUS Now!
Brean Murray Carret & Co. initiates coverage on Ventrus Biosciences (NASDAQ: VTUS) with a Buy. PT $30.00.
Analyst, Jonathan Aschoff, said, "We believe that VEN 309 has blockbuster potential, given its proven efficacy, large target and the lack of competitive prescription hemorrhoid drugs...Ventrus is focused on developing drugs for gastrointestinal indications. The company's lead drug candidate, VEN 309, has completed several Phase 2 trials in patients with hemorrhoids, and within weeks, Phase 3 data will be released that we believe will support approval."
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $10.04 yesterday, with a 52 week range of $6.64-$16.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jonathan Aschoff, said, "We believe that VEN 309 has blockbuster potential, given its proven efficacy, large target and the lack of competitive prescription hemorrhoid drugs...Ventrus is focused on developing drugs for gastrointestinal indications. The company's lead drug candidate, VEN 309, has completed several Phase 2 trials in patients with hemorrhoids, and within weeks, Phase 3 data will be released that we believe will support approval."
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $10.04 yesterday, with a 52 week range of $6.64-$16.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- UPDATE: Howard Weil Upgrades LINN Energy (LINE) to Outperform
- C.K. Cooper Starts Carrizo Oil & Gas (CRZO) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
